Results 61 to 70 of about 2,872,365 (306)

Repurposed oral tapentadol as an intravenous drug of abuse in opioid dependence

Telangana Journal of Psychiatry, 2022
We present to you a case series of a group of individuals who presented to us with a history of intravenous drug abuse of repurposed oral tapentadol. Tapentadol is a synthetic benzenoid with a dual mode of action, as an agonist for the μ-opioid receptor ...
Arshiya Fathima, Minhaj Zafar Nasirabadi, Arifuddin Ahmed, Mazher Ali   +3 more
doaj   +1 more source

The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting

Addiction Science & Clinical Practice, 2021
Background While patient-reported treatment dissatisfaction is considered an important factor in determining the success of substance use disorder treatment, the levels of dissatisfaction with opioid agonist therapies (OAT) and its relationship with the ...
Lindsay Mackay, T. Kerr, N. Fairbairn, Cameron J. Grant, M. Milloy, K. Hayashi   +5 more
semanticscholar   +1 more source

A social ecological model (SEM) to exploring barriers of and facilitators to the implementation of Opioid Agonist Treatment (OAT) programmes in prisons [PDF]

, 2021
First paragraph: Opioid agonist treatment (OAT), an evidence-based treatment for opioid dependence, has been associated with reductions in illicit drug use, injecting drug use, the sharing of injecting equipment and an increase in adherence to ...
Komalasari, Rita, Haw, Sally, Wilson, Sarah, Rita Komalasari, Sarah Wilson, Sally Haw   +5 more
core   +1 more source

Ligand-Specific Regulation of the Endogenous Mu-Opioid Receptor by Chronic Treatment with Mu-Opioid Peptide Agonist [PDF]

, 2013
Since the discovery of the endomorphins (EM), the postulated endogenous peptide agonists of the mu-opioid receptors, several analogues have been synthesized to improve their binding and pharmacological profiles.
Murányi Marianna, Szűcs, Mária, Dochnal Roberta, Kicsi Emese, Kicsi, Emese Gabriella, Fábián Gabriella, Szabó Gyula, Szabó, Gyula, Zentai, András, Bozó, Beáta, Fábián, Gabriella, Birkás Erika, Cinar Resat, Bozó Bea, Birkás, Erika, Kékesi Orsolya Sára, Cinar, Resat, Tóth, Géza, Mácsai Mónika, Mácsai, Mónika, Kékesi, Orsolya, Dochnal, Roberta Beatrix, Tóth Géza, Szűcs Mária, Murányi, Marianna, Zentai András   +25 more
core   +2 more sources

Implementation of a regional quality improvement collaborative to improve care of people living with opioid use disorder in a Canadian setting

BMC Health Services Research, 2019
Background Although opioid agonist therapy is effective in treating opioid use disorders (OUD), retention in opioid agonist therapy is suboptimal, in part, due to quality of care issues. Therefore, we sought to describe the planning and implementation of
Laura Beamish, Zach Sagorin, Cole Stanley, Krista English, Rana Garelnabi, Danielle Cousineau, Rolando Barrios, Jan Klimas   +7 more
doaj   +1 more source

HCV elimination in a Swiss opioid agonist therapy programme – a cohort study

Swiss Medical Weekly, 2022
BACKGROUND: In opioid agonist therapy (OAT) programmes, chronic hepatitis C is highly prevalent and directly observed therapy guarantees optimal adherence. Since 2017, all patients with chronic hepatitis C in Switzerland can be treated with pangenotypic direct-acting antivirals irrespective of liver fibrosis stage.
Bregenzer, Andrea, Krismer, Cornelia, Wendel, Stefanie, Roser, Patrik, Fux, Christoph A.   +4 more
openaire   +3 more sources

Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study

PLoS Medicine, 2022
Background The overdose crisis in North America has prompted system-level efforts to restrict opioid prescribing for chronic pain. However, little is known about how discontinuing or tapering prescribed opioids for chronic pain shapes overdose risk ...
Mary Clare Kennedy, Alexis Crabtree, Seonaid Nolan, Wing Yin Mok, Zishan Cui, Mei Chong, Amanda Slaunwhite, Lianping Ti   +7 more
doaj  

Confounding of the Comparative Safety of Prenatal Opioid Agonist Therapy

Journal of Addiction Research & Therapy, 2015
Prenatal opioid agonist therapy with methadone or buprenorphine prevents maternal illicit opioid use and withdrawal and improves pregnancy outcomes compared to heroin use alone. Historically, methadone has been the first-line opioid agonist therapy for pregnant opioid dependent women; in recent years buprenorphine has become first-line treatment for ...
Susan B, Brogly, Kristen A, Hahn, Sonia Hernandez, Diaz, Martha, Werler   +3 more
openaire   +2 more sources

Personality and attention bias in adults with a history of childhood trauma, and attenuating effects of mu-opioid agonist buprenorphine on attention bias [PDF]

, 2011
The current study compared personality characteristics and cognitive functioning (specifically, attentional bias) in a sample of adults who had experienced childhood trauma (the Trauma group) and a matched healthy control group.
Christ, Bjorn U
core   +1 more source

Large Variation in Provincial Guidelines for Urine Drug Screening During Opioid Agonist Treatment in Canada [PDF]

, 2018
Urine drug screening (UDS) is commonly used to detect or validate self-reported substance use, particularly when beginning and maintaining opioid agonist therapy.
McEachern, Jasmine, Cullen, Walter, Moss, Eloise, Adye-White, Lauren, et al., Klimas, Jan, Jasmine McEachern, Walter Cullen, Jan Klimas, Kelsey C. Priest, Lauren Gorfinkel, Lauren Adye-White, Evan Wood, Eloise Moss   +13 more
core   +1 more source